Short Interest in Elekta AB (OTCMKTS:EKTAY) Decreases By 66.7%

Elekta AB (OTCMKTS:EKTAYGet Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 100 shares, a decrease of 66.7% from the June 30th total of 300 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 5,600 shares, the short-interest ratio is presently 0.0 days.

Elekta Price Performance

EKTAY stock opened at $4.96 on Thursday. Elekta has a 1 year low of $4.36 and a 1 year high of $7.13. The company has a market cap of $1.90 billion, a P/E ratio of 99.22 and a beta of 1.20. The firm has a 50-day moving average of $5.07 and a 200 day moving average of $5.30. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.09 and a quick ratio of 0.86.

Elekta (OTCMKTS:EKTAYGet Free Report) last released its quarterly earnings results on Wednesday, May 28th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). The company had revenue of $503.22 million during the quarter, compared to the consensus estimate of $507.19 million. Elekta had a return on equity of 11.55% and a net margin of 1.15%. On average, sell-side analysts forecast that Elekta will post 0.36 EPS for the current year.

Analysts Set New Price Targets

Separately, Danske downgraded shares of Elekta to a “hold” rating in a research note on Tuesday, June 3rd.

Check Out Our Latest Stock Report on Elekta

Elekta Company Profile

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

See Also

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.